MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Outlook Arena
- Aug 26, 2004 - P&G: Anti-cold is hot!
P&G: Anti-cold is hot!
Introduction to results
P&G Hygiene and Healthcare (P&G) finished FY04 (June ending) with a significant 31% topline growth. A marginal improvement in operating margins and decline in interest burden helped the company clock over 35% bottomline growth during the year. The company had declared a 1:2 bonus issue during the year.
| (Rs m) | 4QFY03 | 4QFY04 | Change | FY03 | FY04 | Change |
| Net sales and licence fees | 949 | 1,436 | 51.4% | 4,424 | 5,772 | 30.5% |
| Other income | 43 | 60 | 39.5% | 148 | 150 | 1.5% |
| Expenditure | 971 | 1,300 | 33.9% | 3,509 | 4,519 | 28.8% |
| Operating profit (EBDIT) | -22 | 136 | - | 915 | 1,254 | 37.1% |
| Operating profit margin (%) | -2.3% | 9.5% | 20.7% | 21.7% | ||
| Interest | 5 | 0 | - | 6 | 4 | -27.3% |
| Depreciation | 43 | 40 | -8.6% | 131 | 128 | -1.8% |
| Profit before tax | -27 | 157 | - | 926 | 1,272 | 37.3% |
| Tax | -11 | 30 | - | 246 | 350 | 42.2% |
| Profit after tax/(loss) | -16 | 127 | - | 680 | 922 | 35.5% |
| Net profit margin (%) | -1.7% | 8.8% | 15.4% | 16.0% | ||
| No. of shares (m) | 21.6 | 32.5 | 21.6 | 32.5 | ||
| Diluted earnings per share (Rs)* | -2.0 | 15.6 | 21.0 | 28.4 | ||
| P/E ratio (x) | 16.3 | |||||
| *(annualised) |
What is the company's business?
P&G is a 65% subsidiary of the FMCG major, P&G USA. In India, the company is a focused two-product company, dominating both segments backed by strong brands, namely ‘Vicks' in the anti-cold segment and ‘Whisper' in feminine care segment. The parent has two other 100% subsidiaries in India which have a dominant shampoo and detergent portfolio. P&G ndertakes contract manufacturing for its parent's detergent portfolio (Ariel, Tide) in India.
All around performance
Core business perks up: The company's key businesses, anti cold (Vicks range) and feminine care (Whisper) performed well during the year. While the Vicks health care folio grew by a strong 26%, feminine care was up 15% YoY. Overall, this business grew by 18% YoY. The Vicks folio's growth seems to have been spear headed by its new launch, Vicks Formula 44 cough syrup. Also, focused advertising and improvement in the distribution chain helped the company. Consequently, the PBIT margins of the business too, improved to nearly 29% (up from 26% levels in FY03).
| (Rs m) | FY03 | FY04 | Change |
| Vicks health care folio | 1,600 | 2,019 | 26.2% |
| % of total revenues | 36.2% | 35.0% | |
| Whisper feminine hygiene folio | 1,420 | 1,636 | 15.2% |
| % of total revenues | 32.1% | 28.3% | |
| Total health & hygiene revenues | 3,020 | 3,655 | 21.0% |
| % of total revenues | 68.3% | 63.3% |
Detergent shine: The key growth driver for the company's topline was no doubt the detergent contract manufacturing business. This division saw a significant 61% growth in revenues. The parent's strategy to garner a bigger chunk of the Indian detergent market by slashing product prices to almost half, has done wonders for this division. It is safe to conclude from the numbers available that the parent has seen a surge in offtake as a result of these price cuts. P&G too has benefited in terms of higher volume of contract manufacturing. Consequently, the division's contribution to overall revenues has gone up from 29% in FY03 to nearly 36% in FY04. PBIT margins of this business too, improved marginally at 5.1%.
| (Rs m) | 4QFY03 | 4QFY04 | Change | FY03 | FY04 | Change |
| Health and hygiene products | 645 | 816 | 26.5% | 3,154 | 3,723 | 18.0% |
| % of revenues | 68.0% | 56.8% | 71.3% | 64.5% | ||
| PBIT margin (%) | 7.8% | 12.4% | 26.4% | 28.8% | ||
| Contract manufacturing | 304 | 620 | 104.2% | 1,270 | 2,050 | 61.4% |
| % of revenues | 32.0% | 43.2% | 28.7% | 35.5% | ||
| PBIT margin (%) | -2.1% | 1.4% | 4.7% | 5.1% | ||
| Total segment revenue | 949 | 1,436 | 51.4% | 4,424 | 5,772 | 30.5% |
| Total PBIT margin (%) | 4.6% | 7.6% | 20.2% | 20.4% |
Expense details: The focus on improving efficiencies, as well as the restructuring of employees has helped the company cut costs as a percentage of sales. In 4QFY04, raw material and packaging costs have seen a significant surge. This seems a result of higher volume of contract manufacturing.
| as a % to sales | 4QFY03 | 4QFY04 | FY03 | FY04 |
| Consumption of raw and packaging material | 27.9% | 54.0% | 32.7% | 40.0% |
| Purchase of trading material | 12.3% | 0.5% | 8.3% | 5.8% |
| Staff cost | 9.7% | 6.0% | 8.3% | 6.4% |
| Other expenditure | 52.4% | 30.0% | 30.1% | 26.0% |
| Total expenditure | 102.3% | 90.5% | 79.3% | 78.3% |
Over the last five quarters The company has really seen topline momentum coming in from the March quarter. This was the period when the parent declared a price war in the detergent segment. Operating margins have remained inconsistent during the past five quarters and have shown signs of pressure, ever since the contract manufacturing business has picked up. The reason being that the margins of this business are very meager at around 5%, as compared to nearly 29% in its health and hygiene business. With detergent prices still ruling low, we believe that contract manufacturing fillip will continue. But that could have a bearing on the margins.
| 4QFY03 | 1QFY04 | 2QFY04 | 3QFY04 | 4QFY04 | |
| Sales growth (YoY) | 10.3% | 20.6% | 18.3% | 40.5% | 51.4% |
| OPM (%) | -2.3% | 23.8% | 31.9% | 20.3% | 9.5% |
| Net profit growth (YoY) | N C* | 13.0% | 11.2% | 22.7% | N C* |
Our view
At the current price of Rs 464, the stock trades at 16.3 times FY04 earnings and market cap. to sales of 2.6x. Investors need to consider that 91% of P&G's total PBIT comes from its core business. Though contract manufacturing will continue to spearhead topline momentum, focus should be on the company's core operations of health and hygiene. The positive thing is that its core business continues to perform well. The company has introduced a new variant of Whisper at a lower price point in southern India. This may increase penetration of the product, thereby aiding volume growth.OUR TOP 5 IDEAS
- India's Revival: A Once-in-a-generation Wealth Making Opportunity
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
P&G HYGIENE SHARE PRICE
Apr 13, 2021 (Close)
TRACK P&G HYGIENE
- Track your investment in P&G HYGIENE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON P&G HYGIENE
P&G HYGIENE 5-YR ANALYSIS
COMPARE P&G HYGIENE WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.